A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03743064|
Recruitment Status : Active, not recruiting
First Posted : November 15, 2018
Last Update Posted : August 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cachexia; Cancer Non Small Cell Lung Cancer||Drug: anamorelin HCl Drug: Placebo Oral Tablet||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||318 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Randomized, Double-Blind, Placebo-Controlled, Multicenter Study|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|
|Actual Study Start Date :||December 18, 2018|
|Actual Primary Completion Date :||July 4, 2022|
|Estimated Study Completion Date :||January 31, 2023|
Experimental: 100 mg anamorelin HCl
100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
Drug: anamorelin HCl
100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
Placebo Comparator: Placebo
Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
Drug: Placebo Oral Tablet
Placebo (administered as matching placebo tablets in the fasted condition)
- body weight [ Time Frame: From baseline until week 12 ]Mean change in body weight
- 5 item Anorexia Symptom Subscale [ Time Frame: From baseline until week 12 ]Mean change in 5-item Anorexia Symptom Subscale
- body weight [ Time Frame: From baseline until week 12 ]Duration of treatment benefit in weight (≥0).
- body weight [ Time Frame: From baseline until week 12 ]Duration of treatment benefit in weight (≥ to a predefined threshold).
- 5 item Anorexia Symptom Subscale [ Time Frame: From baseline until week 12 ]Duration of treatment benefit in anorexia symptoms (≥0), as measured by the 5-item Anorexia Symptom Subscale.
- 5 item Anorexia Symptom Subscale [ Time Frame: From baseline until week 12 ]Duration of treatment benefit in 5-item Anorexia Symptom Subscale (≥ to a predefined threshold).
- FAACT 12-item A/CS domain [ Time Frame: From baseline until week 12 ]Mean change in FAACT 12-item A/CS domain.
- FACIT-F [ Time Frame: From baseline until week 12 ]Mean change in FACIT-F.
- FAACT total score [ Time Frame: From baseline until week 12 ]Mean change in FAACT total score.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Signed written informed consent
- Female or male ≥18 years of age
- Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease
- Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening
- Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤ 37 points on the 12-item FAACT A/CS
Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy.
Patient not receiving systemic anti-cancer treatment is eligible if:
- Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR
- Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle OR
- Patient on palliative care treatment
- ECOG performance status 0,1 or 2 at screening
- AST (SGOT) and ALT (SGPT) ≤ 3 x ULN or if hepatic metastases are present ≤ 5 x ULN
- Adequate renal function, defined as creatinine ≤2 ULN, or calculated creatinine clearance >30 ml/minute
Female patient shall be: a) of non-childbearing potential or b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product.
- Female patient of non-childbearing potential are defined as being in post-menopausal state since at least 1 year; or having documented surgical sterilization or hysterectomy at least 3 months before study participation.
- Reliable contraceptive measures include implants, injectables, combined oral contraceptives, intrauterine devices, vasectomized partner or complete (long term) sexual abstinence.
- The patient must be willing and able to comply with the protocol tests and procedures All inclusion criteria will be checked at screening visit (Visit 1).
- Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)
- Woman who is pregnant or breast-feeding
Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to:
- NCI CTCAE Grade 3 or 4 oral mucositis,
- NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and constipation],
- mechanical obstructions making patient unable to eat, or
- severe depression
- Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to screening. Patient should not have plans to undergo major surgical procedures during the treatment period
- Patient currently taking androgenic compounds (including but not limited to testosterone, testosterone-like agents, oxandrolone, megestrol acetate, corticosteroids, olanzapine, mirtazapine (however, long-term use of mirtazapine for depression for at least four weeks prior to screening is allowed), dronabinol or marijuana (cannabis) or any other prescription medication or off-label products intended to increase appetite or treat unintentional weight loss
- Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites
Patient with uncontrolled or significant cardiovascular disease, including:
- History of myocardial infarction within the past 3 months
- A-V block of second or third degree (may be eligible if currently have a pacemaker)
- Unstable angina
- Congestive heart failure within the past 3 months, if defined as NYHA class III-IV
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)
- Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg diastolic)
- Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic
- Patient on drugs that may prolong the PR or QRS interval durations, such as any of the antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)
- Patient unable to readily swallow oral tablets
- Patient with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption)
- Patient with history of gastrectomy
- Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus
Patient with cachexia caused by other reasons, as determined by the investigator such as:
- Severe COPD requiring use of home O2,
- New York Heart Association (NYHA) class III-IV heart failure
- Uncontrolled thyroid disease
- Patient receiving strong CYP3A4 inhibitors within 14 days of randomization
- Patient currently receiving tube feedings or parenteral nutrition (either total or partial).
- Current excessive alcohol or illicit drug use
- Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Enrollment in a previous study with anamorelin HCl
- Patient actively receiving a concurrent investigational agent, or having received an investigational agent within 28 days of Day 1 All exclusion criteria will be checked at screening visit (Visit 1).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03743064
|Responsible Party:||Helsinn Healthcare SA|
|Other Study ID Numbers:||
2018-002927-40 ( EudraCT Number )
|First Posted:||November 15, 2018 Key Record Dates|
|Last Update Posted:||August 4, 2022|
|Last Verified:||August 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Body Weight Changes
Signs and Symptoms, Digestive